128 related articles for article (PubMed ID: 38913004)
1. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913004
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J; Shah SJ; Petrie MC; Borlaug BA; Abildstrøm SZ; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Verma S; Einfeldt MN; Lindegaard ML; Rasmussen S; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN;
Lancet; 2024 Apr; 403(10437):1635-1648. PubMed ID: 38599221
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
Verma S; Butler J; Borlaug BA; Davies M; Kitzman DW; Shah SJ; Petrie MC; Barros E; Rönnbäck C; Vestergaard LS; Schou M; Ezekowitz JA; Sharma K; Patel S; Chinnakondepalli KM; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913003
[TBL] [Abstract][Full Text] [Related]
4. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
5. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
Butler J; Abildstrøm SZ; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Verma S; Abhayaratna WP; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Núñez J; Perna E; Schou M; Senni M; van der Meer P; von Lewinski D; Wolf D; Altschul RL; Rasmussen S; Kosiborod MN
J Am Coll Cardiol; 2023 Nov; 82(22):2087-2096. PubMed ID: 37993201
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
Eur Heart J; 2024 May; ():. PubMed ID: 38739118
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
J Am Coll Cardiol; 2024 Jul; 84(1):27-40. PubMed ID: 38819334
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA; Kitzman DW; Davies MJ; Rasmussen S; Barros E; Butler J; Einfeldt MN; Hovingh GK; Møller DV; Petrie MC; Shah SJ; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Núñez J; Perna E; Schou M; Senni M; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN
Nat Med; 2023 Sep; 29(9):2358-2365. PubMed ID: 37635157
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Rasmussen S; Davies M; Hovingh GK; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; Van der Meer P; von Lewinski D; Wolf D; Petrie MC;
N Engl J Med; 2023 Sep; 389(12):1069-1084. PubMed ID: 37622681
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN; Petrie MC; Borlaug BA; Butler J; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Treppendahl MB; Verma S; Jensen TJ; Liisberg K; Lindegaard ML; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Shah SJ;
N Engl J Med; 2024 Apr; 390(15):1394-1407. PubMed ID: 38587233
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
15. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Ostrominski JW; Vaduganathan M; Claggett BL; de Boer RA; Desai AS; Dobreanu D; Hernandez AF; Inzucchi SE; Jhund PS; Kosiborod M; Lam CSP; Langkilde AM; Lindholm D; Martinez FA; O'Meara E; Petersson M; Shah SJ; Thierer J; McMurray JJV; Solomon SD
Eur J Heart Fail; 2022 Oct; 24(10):1892-1901. PubMed ID: 36054231
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry.
Teramoto K; Tay WT; Tromp J; Katherine Teng TH; Chandramouli C; Ouwerkerk W; Lawson CA; Huang W; Hung CL; Chopra V; Anand I; Mark Richards A; Lam CSP
Circ Cardiovasc Qual Outcomes; 2023 Jan; 16(1):e009134. PubMed ID: 36484254
[TBL] [Abstract][Full Text] [Related]
19. Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.
Temporelli PL
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i127-i130. PubMed ID: 38867875
[TBL] [Abstract][Full Text] [Related]
20. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
